The U.S. Food and Drug Administration (FDA) together with the Reagan-Udall Foundation for the FDA are hosting a virtual public meeting on psychedelic research, Jan. 31 to Feb. 1. Titled “Advancing Psychedelic Clinical Study Design,” the event aims to explore “empiric approaches to address key issues in psychedelic drug development and research.” In June 2023, the federal agency issued its first draft guidance providing general considerations to industry sponsors developing psychedelic drugs for the treatment of medical conditions. The document was commented on, among others, by specialized law…
